Barclays
ASBP

Barclays’s Aspire Biopharma ASBP Stock Holding History

Barclays’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5 Buy
+1
New +$10 ﹤0.01% 5309
2023
Q2 		– Sell
-583
Closed -$7.35M – 5169
2023
Q1 		$7.35M Hold
583
– – ﹤0.01% 1317
2022
Q4 		$7.21M Hold
583
– – ﹤0.01% 1386
2022
Q3 		$7.1M Hold
583
– – 0.01% 987
2022
Q2 		$6.99M Buy
+583
New +$6.98M ﹤0.01% 1173

Other funds holding ASBP

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays's ASBP Position: Q2 2026 in Review

Barclays opened a new position in Aspire Biopharma (ASBP) in Q2 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #5309 among its holdings. This is a return to the name: Barclays previously reported a position in ASBP as recently as Q1 2023.

Barclays first reported a position in ASBP in Q2 2022 and has held it in 5 quarters since. The position peaked at $7.35M in Q1 2023. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

  • Barclays held 1 share of Aspire Biopharma worth $5 as of Q2 2026.
  • Aspire Biopharma was a new Barclays position in Q2 2026.
  • Aspire Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5309 holding.
  • Barclays first reported a position in Aspire Biopharma in Q2 2022 and has held it in 5 quarters since.
  • Barclays's Aspire Biopharma position peaked at $7.35M in Q1 2023.
  • 13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.